A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer

We conducted a phase I/Ib, open-label, single-arm trial to assess the safety, tolerability and optimal scheduling regimen of OTSGC-A24 cancer vaccine in patients with advanced gastric cancer.